Definium Therapeutics, Inc. (DFTX)
NASDAQ: DFTX · Real-Time Price · USD
31.86
-1.14 (-3.45%)
Nov 13, 2026, 10:47 AM EST - Market open
Definium Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 241.15 | 257.84 | 273.74 | 99.7 | 142.14 | 133.54 |
Short-Term Investments | 805.7 | 153.76 | - | - | - | - |
Cash & Short-Term Investments | 1,047 | 411.59 | 273.74 | 99.7 | 142.14 | 133.54 |
Cash Growth | 400.72% | 50.36% | 174.55% | -29.86% | 6.44% | 66.73% |
Prepaid Expenses | 4.91 | 7.73 | 7.88 | 4.17 | 3.91 | 3.68 |
Total Current Assets | 1,052 | 419.32 | 281.62 | 103.87 | 146.06 | 137.22 |
Goodwill | 19.92 | 19.92 | 19.92 | 19.92 | 19.92 | 19.92 |
Other Intangible Assets | - | - | - | 0.53 | 3.69 | 6.87 |
Other Long-Term Assets | 2.61 | 0.86 | 0.61 | 0.22 | 0.33 | - |
Total Assets | 1,074 | 440.1 | 302.15 | 124.54 | 169.99 | 164 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 9.28 | 5.35 | 2.01 | 4.14 | 2.11 | 4.18 |
Accrued Expenses | 37.13 | 20.45 | 12.83 | 11.63 | 5.88 | 6.23 |
Other Current Liabilities | 21.33 | 40.91 | 24.01 | 16.48 | 9.9 | - |
Total Current Liabilities | 67.73 | 66.7 | 38.85 | 32.25 | 17.89 | 10.41 |
Long-Term Debt | 36.66 | 40.58 | 21.85 | 14.13 | - | - |
Other Long-Term Liabilities | 1.86 | 0.5 | - | 0.03 | 1.18 | 1.93 |
Total Liabilities | 106.25 | 107.77 | 60.7 | 46.41 | 19.08 | 12.34 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Additional Paid-In Capital | 1,839 | 913.91 | 639.51 | 367.99 | 344.76 | 288.29 |
Retained Earnings | -869.72 | -582.67 | -398.88 | -290.2 | -194.47 | -137.67 |
Comprehensive Income & Other | -0.83 | 1.09 | 0.82 | 0.34 | 0.63 | 1.05 |
Shareholders' Equity | 968.03 | 332.33 | 241.45 | 78.13 | 150.92 | 151.66 |
Total Liabilities & Equity | 1,074 | 440.1 | 302.15 | 124.54 | 169.99 | 164 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 36.66 | 40.58 | 21.85 | 14.13 | - | - |
Net Cash (Debt) | 1,010 | 371.01 | 251.89 | 85.58 | 142.14 | 133.54 |
Net Cash Growth | 501.00% | 47.29% | 194.35% | -39.80% | 6.44% | 66.73% |
Net Cash Per Share | 8.85 | 4.15 | 3.57 | 2.19 | 4.61 | 4.88 |
Filing Date Shares Outstanding | 136.9 | 99.7 | 75.37 | 41.33 | 38.06 | 28.58 |
Total Common Shares Outstanding | 136.89 | 98.78 | 75.1 | 41.1 | 37.98 | 28.55 |
Working Capital | 984.03 | 352.62 | 242.77 | 71.63 | 128.16 | 126.81 |
Book Value Per Share | 7.07 | 3.36 | 3.21 | 1.90 | 3.97 | 5.31 |
Tangible Book Value | 948.12 | 312.41 | 221.53 | 57.69 | 127.31 | 124.88 |
Tangible Book Value Per Share | 6.93 | 3.16 | 2.95 | 1.40 | 3.35 | 4.37 |